一种新型四价脑膜炎球菌多糖疫苗的免疫原性和副作用
Immunogenicity and side-effects of a new tetravalent meningococcal polysaccharide vaccine.
作者信息
Ambrosch F, Wiedermann G, Crooy P, George A M
出版信息
Bull World Health Organ. 1983;61(2):317-23.
Abstract
A new tetravalent meningococcal polysaccharide vaccine containing groups A, C, W 135, and Y was administered to 40 healthy adults. The vaccine was well tolerated and bactericidal assay showed mean titre increases for the meningococcal polysaccharide groups A, C, W 135, and Y of 5.0, 7.8, 8.2, and 5.9 log(2) titre steps, respectively. The immunogenicity and side-effects of the vaccine were similar to those associated with monovalent and bivalent vaccines containing group A and C meningococcal polysaccharides.
摘要
一种包含A、C、W 135和Y群的新型四价脑膜炎球菌多糖疫苗被接种给40名健康成年人。该疫苗耐受性良好，杀菌试验显示，A、C、W 135和Y群脑膜炎球菌多糖的平均滴度分别增加了5.0、7.8、8.2和5.9个对数（2）滴度级。该疫苗的免疫原性和副作用与含A群和C群脑膜炎球菌多糖的单价及双价疫苗相似。
相似文献
1
Immunogenicity and side-effects of a new tetravalent meningococcal polysaccharide vaccine.一种新型四价脑膜炎球菌多糖疫苗的免疫原性和副作用
Bull World Health Organ. 1983;61(2):317-23.
2
An evaluation of the immunogenicity and safety of a new trivalent meningococcal polysaccharide vaccine.一种新型三价脑膜炎球菌多糖疫苗的免疫原性和安全性评估。
Vaccine. 2007 Sep 3;25 Suppl 1:A83-91. doi: 10.1016/j.vaccine.2007.04.047. Epub 2007 May 7.
3
[Tetravalent anti-meningococcal vaccine: serologic and clinical evaluation].
Ann Ig. 1989 Nov-Dec;1(6):1293-8.
4
Antibody responses to meningococcal (groups A, C, Y and W135) polysaccharide diphtheria toxoid conjugate vaccine in children who previously received meningococcal C conjugate vaccine.既往接种过脑膜炎球菌C结合疫苗的儿童对脑膜炎球菌（A、C、Y和W135群）多糖-白喉类毒素结合疫苗的抗体反应。
Vaccine. 2006 Mar 24;24(14):2544-9. doi: 10.1016/j.vaccine.2005.12.018. Epub 2005 Dec 27.
5
Serum antibodies to capsular polysaccharide vaccine of group A and C Neisseria meningitidis in military recruits in Italy.意大利新兵中A群和C群脑膜炎奈瑟菌荚膜多糖疫苗的血清抗体情况
Allergol Immunopathol (Madr). 1991 Jan-Feb;19(1):39-41.
6
The capsular polysaccharide of group B Neisseria meningitidis as a vehicle for vaccine development.B群脑膜炎奈瑟菌的荚膜多糖作为疫苗开发的载体。
Contrib Microbiol Immunol. 1989;10:151-65.
7
8
Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age.A群脑膜炎球菌多糖疫苗在3个月至5岁儿童中的临床疗效。
N Engl J Med. 1977 Sep 29;297(13):686-91. doi: 10.1056/NEJM197709292971302.
9
[Immunity against Neisseria meningitidis in different population groups].不同人群中针对脑膜炎奈瑟菌的免疫力
Rev Cubana Med Trop. 1989 Jan-Apr;41(1):135-47.
10
Reactivity and immunogenicity of bivalent (AC) and tetravalent (ACW135Y) meningococcal vaccines containing O-acetyl-negative or O-acetyl-positive group C polysaccharide.含O-乙酰基阴性或O-乙酰基阳性C群多糖的二价（AC）和四价（ACW135Y）脑膜炎球菌疫苗的反应原性和免疫原性
Infect Immun. 1983 Nov;42(2):599-604. doi: 10.1128/iai.42.2.599-604.1983.
引用本文的文献
1
Standing on the shoulders of giants: two centuries of struggle against meningococcal disease.站在巨人的肩膀上：两个世纪以来对抗脑膜炎球菌病的斗争。
Lancet Infect Dis. 2019 Aug;19(8):e284-e294. doi: 10.1016/S1473-3099(19)30040-4. Epub 2019 Apr 30.
2
Meningococcal glycoconjugate vaccines.脑膜炎球菌结合疫苗
Hum Vaccin. 2011 Feb;7(2):170-82. doi: 10.4161/hv.7.2.13717. Epub 2011 Feb 1.
3
Vaccine development in Staphylococcus aureus: taking the biofilm phenotype into consideration.金黄色葡萄球菌疫苗的研发：考虑生物膜表型
FEMS Immunol Med Microbiol. 2010 Aug;59(3):306-23. doi: 10.1111/j.1574-695X.2010.00708.x. Epub 2010 May 29.
4
Prospects for vaccine prevention of meningococcal infection.脑膜炎球菌感染疫苗预防的前景。
Clin Microbiol Rev. 2006 Jan;19(1):142-64. doi: 10.1128/CMR.19.1.142-164.2006.
5
Adverse reactions associated with simultaneous administration of multiple vaccines to travelers.
J Gen Intern Med. 1994 May;9(5):255-60. doi: 10.1007/BF02599650.
6
Vaccination of patients deficient in a late complement component with tetravalent meningococcal capsular polysaccharide vaccine.用四价脑膜炎球菌荚膜多糖疫苗对补体晚期成分缺乏的患者进行疫苗接种。
Clin Exp Immunol. 1995 Apr;100(1):32-9. doi: 10.1111/j.1365-2249.1995.tb03600.x.
本文引用的文献
1
Epidemiology of meningococcal meningitis in Belgium.
J Infect. 1981 Mar;3(1 Suppl):63-70. doi: 10.1016/s0163-4453(81)80010-2.
2
Tetravalent meningococcal polysaccharide vaccine groups A, C, Y, W 135: clinical and serological evaluation.
J Biol Stand. 1982 Oct;10(4):335-9. doi: 10.1016/s0092-1157(82)80010-3.
3
[Investigations on the immune response against meningococcal polysaccharide in children (author's transl)].
Immun Infekt. 1980;8(1):11-8.
4
Control of meningococcal infection in the African meningitis belt by selective vaccination.通过选择性疫苗接种控制非洲脑膜炎带的脑膜炎球菌感染
Lancet. 1980 Apr 5;1(8171):729-32. doi: 10.1016/s0140-6736(80)91230-1.
5
Meningococcal infections. 4. Stability of group A and group C polysaccharide vaccines.脑膜炎球菌感染。4. A群和C群多糖疫苗的稳定性。
Bull World Health Organ. 1971;45(3):287-90.
6
Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-70.脑膜炎球菌感染。2. 1969 - 1970年C群脑膜炎球菌多糖疫苗现场试验。
Bull World Health Organ. 1971;45(3):279-82.
7
Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides.人类对脑膜炎球菌的免疫力。3. A 群、B 群和 C 群脑膜炎球菌多糖的制备及免疫化学性质。
J Exp Med. 1969 Jun 1;129(6):1349-65. doi: 10.1084/jem.129.6.1349.
8
Immunogenicity of the group A and group C meningococcal polysaccharides in children.A群和C群脑膜炎球菌多糖对儿童的免疫原性
J Infect Dis. 1972 May;125(5):509-19. doi: 10.1093/infdis/125.5.509.
9
Quantitative determination of the human immune response to immunization with meningococcal vaccines.对脑膜炎球菌疫苗免疫接种的人体免疫反应的定量测定。
J Clin Invest. 1972 Jan;51(1):89-96. doi: 10.1172/JCI106801.
Zotero 插件